Commons Sense

House of Commons · Written Ministerial Statement

Covid-19 Update

05 September 2022 · Department of Health and Social Care

Proposed by Maggie Throup Con Erewash

NHS

Summarised by AI from the official record, so it can contain mistakes.

View on Parliament.uk

At a glance

Key points

  • The UK government is deploying authorised bivalent vaccines and Nuvaxovid for the autumn booster programme.
  • The update includes details on the government's liabilities to secure further vaccine supply.
  • The statement focuses on the ongoing Covid-19 vaccination programme in the UK.

Issue summary

The statement provides an update on the ongoing Covid-19 vaccination programme in the UK, focusing on the autumn booster programme and new vaccine authorisations.

Action requested

The government is deploying authorised bivalent vaccines and Nuvaxovid for eligible individuals as part of the autumn booster programme. The House is updated on the liabilities Her Majesty’s Government has taken to secure further vaccine supply.

Key facts

  • Over 126 million doses have been provided, including 45.2 million first doses, 42.6 million second doses and 33.5 million third primary and booster doses in the UK.
  • The JCVI advises that for the 2022 autumn booster programme, certain groups should be offered a Covid-19 booster vaccine to optimise protection against severe Covid-19 over winter 2022/23.
  • Moderna’s BA1/wild-type bivalent vaccine was authorised on 12 August 2022 and Pfizer’s BA1/wild type bivalent vaccine on 3 September 2022 by the MHRA.
  • Nuvaxovid, the Novavax Covid-19 vaccine, may be used off-label as a booster dose for persons aged 18 years and above when no alternative clinically suitable UK-approved Covid-19 vaccine is available.
▸ Assessment & feedback
Summary accuracy